Indomethacin prophylaxis revisited: changing practice and supportive evidence

K AlFaleh1

  • 1Neonatal Intensive Care Unit, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia. kfaleh@ksu.edu.sa

Insights

Indomethacin prophylaxis in extremely low birth weight infants prevents short-term issues but not long-term neurosensory outcomes or bronchopulmonary dysplasia. More research is needed on its overall effectiveness.

Area of Science:

  • Neonatalogy
  • Perinatal Medicine
  • Developmental Pediatrics

Background:

  • Patent ductus arteriosus (PDA) and related complications are common in extremely low birth weight (ELBW) infants.
  • Short-term interventions like indomethacin prophylaxis aim to prevent adverse outcomes.
  • The long-term impact of these interventions on neurodevelopment remains unclear.

Purpose of the Study:

  • To summarize evidence on indomethacin prophylaxis in ELBW infants.
  • To explore reasons for the lack of long-term neurosensory benefits.
  • To critically analyze the methodology of key trials, including the Trial of Indomethacin Prophylaxis for Preterms.

Main Methods:

  • Systematic review of existing evidence.
  • Critical analysis of the Trial of Indomethacin Prophylaxis for Preterms methodology.
  • Discussion of methodological concerns including composite outcomes, statistical power, and predictive validity of cognitive assessments.

Main Results:

  • Indomethacin prophylaxis effectively reduces short-term complications like PDA and intraventricular hemorrhage.
  • This prophylaxis does not improve long-term neurosensory outcomes or prevent bronchopulmonary dysplasia.
  • Methodological limitations in trials may obscure the true effects of indomethacin.

Conclusions:

  • Conclusive evidence supporting routine indomethacin prophylaxis in ELBW infants is lacking.
  • Future research should consider parental preferences, fluid restriction interactions, and early PDA management strategies.
  • Further investigation is required to clarify the role of indomethacin prophylaxis in ELBW infant care.
Abstract

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...